PPT Slide
- Initiated two Phase 2 “proof-of-concept” trials with alfimeprase
- Successfully completed interim analysis for Phase 2 PAO trial
- Completed ~$28MM financing
- Successfully monetizing a portion of our non-core assets
- Sequenom license agreement provides up front revenue, potential royalties and patent prosecution savings
- Appointed Mark Perry of Gilead Sciences to Nuvelo’s board of directors
- Secured sell-side analyst coverage